ESR1 and breast cancer: Even though the first attempts to identify CDKN1B mutation in BC were unsuccessful (53), more recent efforts by whole genome sequencing revealed that mutations affecting CDKN1B are present and can represent driver genetic lesions in the estrogen receptor (ER)-positive (LBC) subtype.